

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Singular Health Group Limited
ABN	58 639 242 765

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Denning Chong
Date of last notice	20 March 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	(1) Indirect (2) Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	(1) Securities held by JCC Health Pty Ltd , an entity controlled by Mr Chong, and of which he is a beneficiary (2) Securities held by JDE Capital Pty Limited , an entity controlled by Mr Chong and of which he is a beneficiary
Date of change	26 June 2023
No. of securities held prior to change	(1)(i) 4,640,869 FULLY PAID ORDINARY SHARES (1)(ii) 1,200,000 CLASS A PERFORMANCE RIGHTS (1)(iii) 1,200,000 CLASS B PERFORMANCE RIGHTS (1)(iv) 4,500,000 UNLISTED OPTIONS (\$0.30, 10 February 2025) (1)(v) 1,500,000 PERFORMANCE RIGHTS, SUBJECT TO VESTING, EXPIRING 23 DECEMBER 2025 (2)(i) 418,749 FULLY PAID ORDINARY SHARES

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Class	FULLY PAID ORDINARY SHARES, UNLISTED OPTIONS
Number acquired	1,818,182 FULLY PAID ORDINARY SHARES 1,818,182 UNLISTED OPTIONS (\$0.10, 26 June 2026)
Number disposed	NIL
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$100,000
No. of securities held after change	(1)(i) 4,640,869 FULLY PAID ORDINARY SHARES (1)(ii) 1,200,000 CLASS A PERFORMANCE RIGHTS (1)(iii) 1,200,000 CLASS B PERFORMANCE RIGHTS (1)(iv) 4,500,000 UNLISTED OPTIONS (\$0.30, 10 February 2025) (1)(v) 1,500,000 PERFORMANCE RIGHTS, SUBJECT TO VESTING, EXPIRING 23 DECEMBER 2025 (2)(i) 2,236,931 FULLY PAID ORDINARY SHARES (2)(i) 1,818,182 UNLISTED OPTIONS (\$0.10, 26 June 2026)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	PARTICIPATION IN CAPITAL RAISING AS APPROVED BY SHAREHOLDERS AT GENERAL MEETING HELD ON 16 JUNE 2023.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.